CN114681674A - Filling material for promoting blood vessel, collagen regeneration and adipose tissue repair, and preparation method and application thereof - Google Patents
Filling material for promoting blood vessel, collagen regeneration and adipose tissue repair, and preparation method and application thereof Download PDFInfo
- Publication number
- CN114681674A CN114681674A CN202210351631.2A CN202210351631A CN114681674A CN 114681674 A CN114681674 A CN 114681674A CN 202210351631 A CN202210351631 A CN 202210351631A CN 114681674 A CN114681674 A CN 114681674A
- Authority
- CN
- China
- Prior art keywords
- adipose tissue
- acellular matrix
- adipose
- minutes
- filling material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000577 adipose tissue Anatomy 0.000 title claims abstract description 55
- 238000011049 filling Methods 0.000 title claims abstract description 40
- 239000000463 material Substances 0.000 title claims abstract description 31
- 102000008186 Collagen Human genes 0.000 title claims abstract description 26
- 108010035532 Collagen Proteins 0.000 title claims abstract description 26
- 229920001436 collagen Polymers 0.000 title claims abstract description 26
- 230000008929 regeneration Effects 0.000 title claims abstract description 25
- 238000011069 regeneration method Methods 0.000 title claims abstract description 25
- 210000004204 blood vessel Anatomy 0.000 title claims abstract description 21
- 230000001737 promoting effect Effects 0.000 title claims abstract description 19
- 230000017423 tissue regeneration Effects 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 72
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 72
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 72
- 239000011159 matrix material Substances 0.000 claims abstract description 64
- 239000002131 composite material Substances 0.000 claims abstract description 32
- 239000007787 solid Substances 0.000 claims abstract description 27
- 238000003756 stirring Methods 0.000 claims abstract description 21
- 238000000227 grinding Methods 0.000 claims abstract description 19
- 238000002156 mixing Methods 0.000 claims abstract description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 9
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 9
- 239000001110 calcium chloride Substances 0.000 claims abstract description 9
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 9
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 9
- 239000000661 sodium alginate Substances 0.000 claims abstract description 9
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 9
- 238000005119 centrifugation Methods 0.000 claims abstract description 7
- 229960003964 deoxycholic acid Drugs 0.000 claims abstract description 7
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims abstract description 7
- 229960002713 calcium chloride Drugs 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 15
- 238000005406 washing Methods 0.000 claims description 12
- 238000007710 freezing Methods 0.000 claims description 10
- 230000008014 freezing Effects 0.000 claims description 10
- 239000002504 physiological saline solution Substances 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 7
- 238000004945 emulsification Methods 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 239000002537 cosmetic Substances 0.000 claims description 3
- 230000001678 irradiating effect Effects 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 210000004872 soft tissue Anatomy 0.000 claims description 2
- 238000010257 thawing Methods 0.000 claims description 2
- 229920004890 Triton X-100 Polymers 0.000 claims 2
- 239000013504 Triton X-100 Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 13
- 230000006870 function Effects 0.000 abstract description 8
- 230000034196 cell chemotaxis Effects 0.000 abstract description 2
- 239000000499 gel Substances 0.000 description 57
- 230000000052 comparative effect Effects 0.000 description 26
- 239000007924 injection Substances 0.000 description 26
- 238000002347 injection Methods 0.000 description 26
- 239000007864 aqueous solution Substances 0.000 description 23
- 101000639972 Homo sapiens Sodium-dependent dopamine transporter Proteins 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 9
- 230000033115 angiogenesis Effects 0.000 description 8
- 239000000945 filler Substances 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000003399 chemotactic effect Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 210000001789 adipocyte Anatomy 0.000 description 4
- 230000003796 beauty Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000004519 grease Substances 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000005482 chemotactic factor Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000000053 physical method Methods 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000010008 shearing Methods 0.000 description 3
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000002327 eosinophilic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/025—Other specific inorganic materials not covered by A61L27/04 - A61L27/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a preparation method of a filling material for promoting blood vessel and collagen regeneration and adipose tissue repair, which is characterized in that adipose tissue is repeatedly frozen and thawed for a plurality of times; centrifuging the fully thawed adipose tissue; the adipose tissues are crushed evenly by violent stirring, and are centrifuged after standing and demulsification; treating flocculent solid obtained by centrifugation with TritonX-100 solution and sodium deoxycholate, and lyophilizing to remove water to obtain acellular matrix; mixing the acellular matrix, hyaluronic acid, sodium alginate and calcium chloride, grinding to obtain powder, and mixing with normal saline in proportion to obtain the acellular matrix/hyaluronic acid composite gel. The filling material prepared by the method can obviously improve the filling effect and has better functions of blood vessel regeneration, collagen regeneration, cell chemotaxis and the like.
Description
Technical Field
The invention relates to the field of medical cosmetic materials, in particular to a filling material for promoting blood vessel and collagen regeneration and adipose tissue repair, a preparation method and application thereof.
Background
The research and development of the human body filling material is one of the fields of the key development of the medical beauty treatment (hereinafter, medical beauty) industry in China. At present, medical and aesthetic filling materials mainly comprise fillers such as hyaluronic acid, polylactic acid, silica gel and the like. However, the filling material at the present stage has poor effect, which mainly comprises: the hyaluronic acid and polylactic acid are heterogeneous materials with single function, only play a role in filling, have no regeneration and repair function, need to be injected for many times after being degraded in vivo, and are expensive. Research has shown that adipose tissue regeneration and repair depends on the properties of the filling material such as promoting blood vessels, collagen regeneration and fat cell chemotaxis. The development of the filling material with the functions is a key link for promoting the further development of the medical and beauty industry.
Research shows that the acellular matrix is rich in a large number of growth chemotactic factors and has good angiogenesis and adipocyte chemotactic properties. Document CN108178868 discloses a method for preparing acellular matrix, but organic reagents such as isopropyl alcohol are used in the process, which easily destroy growth chemotactic factors and natural physical space structures in the acellular matrix, and influence the tissue regeneration performance of the acellular matrix. At present, acellular matrix preparation by a physical method is developed, but the obtained acellular matrix has overlarge particles and poor dispersibility, and is difficult to be clinically popularized as an injection filler. And the injected cell matrix can not reach a uniform dispersion system under the skin, thereby seriously influencing the filling plasticity effect. Therefore, it is necessary to develop an acellular matrix filling material which has good dispersion performance and can obviously promote the regeneration of tissue collagen, so as to be suitable for the development of the medical cosmetology industry.
Disclosure of Invention
In view of the defects in the prior art, the invention aims to provide the filling material for promoting the regeneration of blood vessels and collagen and the repair of adipose tissues, and the preparation method and the application thereof.
The purpose of the invention is realized by the following technical scheme:
one of the purposes of the invention is to provide a preparation method of a filling material for promoting blood vessel, collagen regeneration and adipose tissue repair, which comprises the following steps:
repeatedly freezing and thawing adipose tissues for several times;
centrifuging the completely thawed adipose tissues to remove water and partial grease in the adipose tissues;
the adipose tissues are crushed evenly by violent stirring, and are centrifuged after standing and demulsification;
treating flocculent solid obtained by centrifugation with TritonX-100 solution and sodium deoxycholate, and lyophilizing to remove water to obtain acellular matrix;
mixing the acellular matrix, hyaluronic acid, sodium alginate and calcium chloride, grinding to obtain powder, and mixing with normal saline in proportion to obtain the acellular matrix/hyaluronic acid composite gel.
Further, the method comprises the following steps:
step 1) collecting and sub-packaging adipose tissues into a centrifuge tube, freezing for 20-30 minutes at-24 ℃, then unfreezing in a water bath at 37 ℃, and repeating the operation for 5-7 times;
step 2) centrifuging the completely thawed adipose tissues at the centrifugal rotation speed of 3000-4000 rpm for 10-15 minutes;
step 3) adding the adipose tissues centrifuged in the step 2) into a tissue pulverizer, pulverizing and dispersing the adipose tissues through violent stirring, extruding the grease out of the adipose tissues through stirring shearing force, wherein the stirring revolution is 3000rpm-4000rpm, and the stirring time is 5 minutes-10 minutes;
step 4) placing the adipose tissues uniformly stirred and crushed in the step 3) at 4 ℃, standing for 0.5-1 hour to remove emulsification, and then centrifuging at the rotating speed of 3000-4000 rpm for 5-10 minutes;
step 5) collecting the lower-layer flocculent solid obtained after centrifugation in the step 4), washing with physiological saline, adding 1% TritonX-100 solution, soaking for 5-10 minutes, centrifuging to remove the TritonX-100 solution, and washing with physiological saline;
step 6), adding 1% sodium deoxycholate, incubating for 5-10 minutes, centrifuging, collecting lower flocculent solids, and washing with normal saline;
step 7) putting the flocculent solid collected in the step 6) into a refrigerator at the temperature of-24 ℃ for freezing for 2-4 hours, and carrying out freeze-drying and dewatering by a freeze-drying machine to obtain a solid massive acellular matrix;
step 8) mixing 0.5g of the acellular matrix prepared in the step 7), 0.45g of hyaluronic acid, 0.05g of sodium alginate and 0.02g of calcium chloride, and grinding for 30-60 minutes by using a vibration ball mill at a grinding speed of 2000-3000 r/min, wherein the specification of grinding balls is 20 mm, and the sample size is less than 10 microns;
step 9) placing the powder obtained by grinding in the step 8) under an ultraviolet lamp for irradiating for 2-4 hours, sterilizing, and placing in a refrigerator at-24 ℃;
step 10) mixing the sterilized powder obtained in the step 9) with normal saline according to the ratio of 1: 5-1: 50, stirring uniformly, standing in a refrigerator at 4 ℃ for 24-36 hours, and removing bubbles in the gel to obtain the acellular matrix/hyaluronic acid composite gel.
Further, the adipose tissue in the step 1) is human adipose tissue or porcine adipose tissue.
Further, the hyaluronic acid in the step 8) is 180 ten thousand molecular weight.
Another object of the present invention is to provide a filling material for promoting blood vessel, collagen regeneration and adipose tissue repair, prepared according to the above method.
The invention also aims to provide the application of the filling material for promoting blood vessel, collagen regeneration and adipose tissue repair in soft tissue filling and medical cosmetic filling.
The invention has the outstanding effects that:
the preparation method of the filling material for promoting blood vessel and collagen regeneration and adipose tissue repair, disclosed by the invention, has the advantages that the acellular matrix is prepared by a physical method instead of a method using a chemical agent in the prior art, the growth chemotactic factor and the natural physical space structure in the acellular matrix are not damaged, the tissue regeneration performance of the acellular matrix is not influenced, the obtained acellular matrix has small particles, good dispersibility and good plastic filling effect, and can be clinically popularized as an injection filling agent. The filling material for promoting blood vessel and collagen regeneration and adipose tissue repair can replace the existing filling material, and simultaneously has the functions of regeneration and repair, reduces degradation in vivo and injection times, thereby reducing the treatment cost.
The following detailed description of the embodiments of the present invention is provided in connection with the examples to facilitate understanding and understanding of the technical solutions of the present invention.
Drawings
FIG. 1 is a graph showing the trend of the change in volume of hyaluronic acid gel, human adipose acellular matrix aqueous solution of comparative example 1 and human DAT/HA composite gel of example 1 after being injected subcutaneously into mice;
FIG. 2 is a graph showing the results of B-mode ultrasound detection in each group of hyaluronic acid gel, human adipose acellular matrix aqueous solution of comparative example 1 and human DAT/HA composite gel of example 1 after 2 months of injection;
FIG. 3 is the anatomical morphology of the human-derived adipose acellular matrix aqueous solution of comparative example 1 and the human-derived DAT/HA composite gel of example 1 after 2 months of injection;
FIG. 4 is a comparison graph of morphology of the human-derived adipose acellular matrix aqueous solution of comparative example 1 and the human-derived DAT/HA composite gel of example 1 before and after injection under an electron microscope;
FIG. 5 is a graph comparing HE staining, Masson staining and immunohistochemical staining of injections of each group 2 months after injection of the aqueous solution of the human adipose acellular matrix of comparative example 1 and the human DAT/HA complex gel of example 1;
fig. 6 is liver and kidney function index diagrams of various groups of mice after hyaluronic acid gel, human-derived adipose acellular matrix aqueous solution of comparative example 1 and human-derived DAT/HA composite gel of example 1 are injected.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments.
Example 1: preparation of human source acellular matrix/hyaluronic acid composite gel
The preparation method of this example includes the following steps:
step 1) collecting and sub-packaging human adipose tissues into a 50ml centrifuge tube, freezing for 20 minutes at-24 ℃, then unfreezing in a 37 ℃ water bath condition, and repeating the operation for 5 times;
step 2) centrifuging the completely thawed adipose tissues at the centrifugal rotating speed of 3000rpm for 15 minutes;
step 3) adding the adipose tissues centrifuged in the step 2) into a tissue pulverizer, pulverizing and dispersing the adipose tissues through violent stirring, extruding the grease out of the adipose tissues through stirring shearing force, wherein the stirring revolution is 3000rpm, and the stirring time is 10 minutes;
step 4) placing the adipose tissues uniformly stirred and crushed in the step 3) at 4 ℃, standing for 0.5 hour to remove emulsification, and then centrifuging at the rotating speed of 3000rpm for 10 minutes;
step 5) collecting the lower-layer flocculent solid obtained after centrifugation in the step 4), washing the lower-layer flocculent solid with physiological saline for 3 times, adding 1% TritonX-100 solution to soak the flocculent solid for 5 minutes, centrifuging the flocculent solid to remove the TritonX-100 solution, and washing the flocculent solid with the physiological saline for 3 times;
step 6), adding 1% sodium deoxycholate, incubating for 5 minutes, centrifuging, collecting lower-layer flocculent solids, and washing for 3 times by using normal saline;
step 7) putting the flocculent solid collected in the step 6) into a refrigerator at the temperature of-24 ℃ for freezing for 2 hours, and carrying out freeze-drying and dewatering by a freeze-drying machine to obtain a solid massive acellular matrix;
step 8) mixing 0.5g of the acellular matrix prepared in the step 7), 0.45g of hyaluronic acid (180 ten thousand molecular weight), 0.05g of sodium alginate and 0.02g of calcium chloride, and grinding for 30 minutes by using a vibration ball mill at a grinding speed of 2000 revolutions per minute, wherein the specification of a grinding ball is 20 millimeters, and the sample size is less than 10 micrometers;
step 9) spreading the powder obtained by grinding in the step 8) in a culture dish, placing under an ultraviolet lamp for 2 hours, sterilizing, and placing in a refrigerator at-24 ℃;
step 10) mixing the sterilized powder obtained in the step 9) with normal saline according to the ratio of 1: 5, stirring uniformly, standing in a refrigerator at 4 ℃ for 24 hours, and removing air bubbles in the gel to obtain the acellular matrix/hyaluronic acid composite gel (DAT/HA composite gel). The bubble-free DAT/HA composite gel was packaged in 1 mL/vial and refrigerated at 4 ℃ for use.
Example 2: preparation of pig source acellular matrix/hyaluronic acid composite gel
The preparation method of this example includes the following steps:
step 1) collecting and sub-packaging pig-derived adipose tissues into 50ml centrifuge tubes, freezing for 30 minutes at-24 ℃, then unfreezing in a 37 ℃ water bath condition, and repeating the operation for 7 times;
step 2) centrifuging the completely thawed adipose tissues at the rotation speed of 4000rpm for 10 minutes;
step 3) adding the adipose tissues centrifuged in the step 2) into a tissue pulverizer, pulverizing and dispersing the adipose tissues through violent stirring, extruding the grease out of the adipose tissues through stirring shearing force, wherein the stirring revolution is 4000rpm, and the stirring time is 5 minutes;
step 4) placing the adipose tissues uniformly stirred and crushed in the step 3) at 4 ℃, standing for 1 hour to remove emulsification, and then centrifuging at the rotating speed of 4000rpm for 5 minutes;
step 5) collecting the lower-layer flocculent solid obtained after centrifugation in the step 4), washing the lower-layer flocculent solid with physiological saline for 3 times, adding 1% TritonX-100 solution to soak the flocculent solid for 10 minutes, centrifuging the flocculent solid to remove the TritonX-100 solution, and washing the flocculent solid with the physiological saline for 3 times;
step 6), adding 1% sodium deoxycholate, incubating for 10 minutes, centrifuging, collecting lower-layer flocculent solids, and washing for 3 times by using normal saline;
step 7) freezing the flocculent solid collected in the step 6) in a refrigerator at the temperature of-24 ℃ for 4 hours, and performing freeze-drying and dewatering by using a freeze dryer to obtain a solid massive acellular matrix;
step 8) mixing 0.5g of the acellular matrix prepared in the step 7), 0.45g of hyaluronic acid (180 ten thousand molecular weight), 0.05g of sodium alginate and 0.02g of calcium chloride, and grinding for 60 minutes by using a vibration ball mill at the grinding speed of 3000 revolutions per minute, wherein the specification of grinding balls is 20 millimeters, and the sample size is less than 10 micrometers;
step 9) spreading the powder obtained by grinding in the step 8) in a culture dish, placing under an ultraviolet lamp for 4 hours, sterilizing, and placing in a refrigerator at-24 ℃;
step 10) mixing the sterilized powder obtained in the step 9) with normal saline according to the ratio of 1: 50, stirring uniformly, standing in a refrigerator at 4 ℃ for 36 hours, and removing bubbles in the gel to obtain the acellular matrix/hyaluronic acid composite gel (DAT/HA composite gel). The bubble-free DAT/HA composite gel was packaged in 1 mL/vial and refrigerated at 4 ℃ for use.
Comparative example 1: preparation of human-derived adipose acellular matrix (DAT) solution
This example differs from example 1 in that hyaluronic acid (180 ppm molecular weight), sodium alginate and calcium chloride were not added in step 8), and the others were identical to example 1.
Comparative example 2: preparation of porcine-derived fat acellular matrix (DAT) solution
This example differs from example 2 in that hyaluronic acid (180 ppm molecular weight), sodium alginate and calcium chloride were not added in step 8), and the others were identical to example 2.
Examples of the experiments
The human DAT/HA composite gel filling effect evaluation experiment and the experimental results in the embodiment 1 of the invention are as follows:
1. tendency of volume change of filler:
the hyaluronic acid gel content of each group was 2.5%, and the fat acellular matrix content was 2.5%, as measured by measuring the volume change of the injection every 1 week by injecting 1ml of Hyaluronic Acid (HA) gel, human fat acellular matrix (DAT) aqueous solution (comparative example 1), and human DAT/HA complex gel (example 1) into the skin on the back of the mouse, respectively.
The experimental results are as follows:
fig. 1 shows that the volumes of the materials injected into the back skin are similar, hyaluronic acid is basically absorbed by the body after being injected into the skin for 3 weeks, the human fat acellular matrix aqueous solution (comparative example 1) and the human DAT/HA complex gel (example 1) have a temporary volume reduction due to water loss in the first 3 weeks after injection, and then gradually increase due to physiological processes such as chemotactic cell generation and collagen secretion. And the human DAT/HA composite gel (example 1) HAs a pore structure, so that the cell chemotactic growth is more facilitated, and the corresponding volume of the human DAT/HA composite gel is higher than that of the human fat acellular matrix aqueous solution (comparative example 1).
2. And (3) observing the morphology of the filler:
after 2 months of injection of the hyaluronic acid gel, the human adipose acellular matrix aqueous solution (comparative example 1) and the human DAT/HA composite gel (example 1), the morphology and size of each group of injection materials were observed by B-ultrasound.
The experimental results are as follows:
the results in fig. 2 show that no graft retention is seen at the site of hyaluronic acid gel injection under ultrasonography B, which indicates that hyaluronic acid gel is completely absorbed by the body; after 2 months of injecting the human-derived fat acellular matrix aqueous solution (comparative example 1), the center of the B-ultrasonic downward-moving plant presents uneven echo, the injected substance presents a block shape and forms an irregular low-echo-shadow liquid sac cavity, and the periphery of the graft is formed by a high-echo-shadow envelope; after 2 months of injection of the human DAT/HA complex gel (example 1), the B-ultrasound injection showed a uniform flat echogenic mass image, fused with subcutaneous tissue and dorsal musculature, with clear borders and no envelope around. The experimental result shows that the pure hyaluronic acid gel is easy to digest and absorb by organisms and does not have a long-term filling effect, the human-derived fat acellular matrix aqueous solution (comparative example 1) is not easy to digest and HAs long filling time, but the human-derived DAT/HA composite gel (example 1) can improve the dispersibility of the fat acellular matrix and prevent aggregation in the filling process through the hyaluronic acid gel, and the filling effect is optimal.
3. Evaluation of the effect of angiogenesis:
after 2 months of injection of hyaluronic acid gel, human-derived fat acellular matrix aqueous solution (comparative example 1) and human-derived DAT/HA composite gel (example 1), the injection is surgically excised, and the morphology, size and blood vessel growth status of each group of injection materials are observed.
The experimental results are as follows:
FIG. 3 shows that hyaluronic acid is completely absorbed by the body, and the human adipose acellular matrix aqueous solution (comparative example 1) is white spherical tissue, hard in texture, provided with a significant envelope, and has blood vessels crawling on the spherical surface, which can promote the regeneration of blood vessels. The human DAT/HA complex gel (example 1) presents a yellowish-brown opaque fat pad-like tissue, is soft, HAs no obvious envelope, and HAs microangiogenesis on the surface of the filler and grows into the tissue. The human DAT/HA composite gel (example 1) is proved to have good function of promoting angiogenesis and the best filling effect.
4. Evaluation of cell chemotactic Effect:
scanning electron microscope samples are prepared by the prepared human-derived adipose acellular matrix aqueous solution (comparative example 1) and human-derived DAT/HA composite gel (example 1) and filling after 2 months of injection, and the microscopic morphology and the cell abundance of the gel are observed by the scanning electron microscope.
The experimental results are as follows:
FIG. 4 shows that the aqueous solution of human adipose acellular matrix (comparative example 1) before injection has a microscopic morphology of filaments, and has partial aggregation and nonuniform dispersion. The human DAT/HA complex gel (example 1) was uniformly dispersed and no significant blocky aggregates were present. After injection, the human-derived fat acellular matrix aqueous solution (comparative example 1) had a small number of spherical objects (cells) on the filler, but the number was small, and the dispersion was not uniform, whereas the human-derived DAT/HA composite gel (example 1) had a large number of spherical objects (cells) on the filler, and the spherical objects (cells) were uniformly dispersed. Compared with the human adipose acellular matrix aqueous solution (comparative example 1), the human DAT/HA complex gel (example 1) is more beneficial to the growth of cells and HAs stronger cell chemotactic function.
5. Microscopic adipocyte chemotaxis and regeneration, collagen and angiogenesis effect evaluation:
after 2 months of injection of the human-derived adipose acellular matrix aqueous solution (comparative example 1) and the human-derived DAT/HA complex gel (example 1), the material microcontaining effect was observed by HE staining, Masson staining, and immunohistochemical staining, respectively.
The experimental results are as follows:
FIG. 5 shows that HE sections after injection of human adipose acellular matrix aqueous solution (comparative example 1) showed significant envelope formation, accumulation of irregular eosinophilic staining mass in the bursa, massive inflammatory cell infiltration and debris residue; after the human DAT/HA composite gel (example 1) is injected, no obvious envelope is formed, a small amount of inflammatory cells infiltrate into the center of the graft, obvious adipocyte generation and aggregation are realized, and eosinophilic staining extracellular matrix is densely arranged and relatively regular. Masson staining showed that human adipose acellular matrix in water (comparative example 1) had significant collagen fiber formation in the graft envelope capsule, and the density of arrangement of collagen fibers in the capsule was loose and not closely related. The human DAT/HA composite gel (example 1) injected is free from the formation of a capsule, the outer edge of the gel HAs obvious angiogenesis (arrow), collagen fibers are regularly and orderly arranged, collagen in the center of the graft is relatively less, and the collagen is infiltrated by more macrophages. Immunohistochemical staining showed that injection of human adipose acellular matrix aqueous solution (comparative example 1) had only a small amount of small angiogenesis (arrows) staining positive for a-SMA in the envelope, without any angiogenesis in the capsule. Injection of human DAT/HA complex gel (example 1) the graft exhibited diffuse small angiogenesis (arrows) and apparently vascular luminal formation in the center of the graft.
6. DAT/HA Complex gel safety assessment:
after hyaluronic acid gel, human adipose acellular matrix aqueous solution (comparative example 1) and human DAT/HA composite gel (example 1) were injected, blood of each group of mice was collected, lactate dehydrogenase LDH, glutamic pyruvic transaminase ALT and serum creatinine Scr which reflect the functions of the heart, liver and kidney of the body were detected, and the safety of the material was verified.
The experimental results are as follows:
the results in fig. 6 show that there is no obvious functional damage to heart, liver and kidney of mice injected with hyaluronic acid gel, human fat acellular matrix aqueous solution (comparative example 1) and human DAT/HA composite gel (example 1), and there is no statistical difference in functional indexes of heart, liver and kidney, such as LDH, ALT and Scr, of each group, which are within the range of heart, liver and kidney functional indexes of mice.
In conclusion, the DAT/HA composite gel is prepared by a physical method, shows excellent regeneration performance compared with common hyaluronic acid and fat acellular matrix in the aspects of volume after injection, anatomical morphology, under-lens observation, B-ultrasonic display, immunofluorescence, liver and kidney functions and the like, HAs small particles, better dispersibility and good plastic filling effect, and is a high-quality novel medical and beauty filling product.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art should be considered to be within the technical scope of the present invention, and the technical solutions and the inventive concepts thereof according to the present invention should be equivalent or changed within the scope of the present invention.
Claims (6)
1. A preparation method of a filling material for promoting blood vessel, collagen regeneration and adipose tissue repair is characterized by comprising the following steps:
repeatedly freezing and thawing the adipose tissue for several times;
centrifuging the fully thawed adipose tissue;
the adipose tissues are crushed evenly by violent stirring, and are centrifuged after standing and demulsification;
treating flocculent solid obtained by centrifugation with TritonX-100 solution and sodium deoxycholate, and lyophilizing to remove water to obtain acellular matrix;
mixing the acellular matrix, hyaluronic acid, sodium alginate and calcium chloride, grinding to obtain powder, and mixing with normal saline in proportion to obtain the acellular matrix/hyaluronic acid composite gel.
2. A method for preparing a filling material for promoting blood vessel, collagen regeneration and adipose tissue repair according to claim 1, comprising the steps of:
step 1) collecting and sub-packaging adipose tissues into a centrifuge tube, freezing for 20-30 minutes at-24 ℃, then unfreezing in a water bath at 37 ℃, and repeating the operation for 5-7 times;
step 2) centrifuging the completely thawed adipose tissues at the centrifugal rotation speed of 3000-4000 rpm for 10-15 minutes;
step 3) adding the adipose tissues centrifuged in the step 2) into a tissue pulverizer, wherein the stirring speed is 3000rpm-4000rpm, and the stirring time is 5 minutes-10 minutes;
step 4) placing the adipose tissues uniformly stirred and crushed in the step 3) at 4 ℃, standing for 0.5-1 hour to remove emulsification, and then centrifuging at the rotating speed of 3000-4000 rpm for 5-10 minutes;
step 5) collecting the lower-layer flocculent solid obtained after centrifugation in the step 4), washing with physiological saline, adding 1% Triton X-100 solution, soaking for 5-10 minutes, centrifuging to remove the Triton X-100 solution, and washing with physiological saline;
step 6), adding 1% sodium deoxycholate, incubating for 5-10 minutes, centrifuging, collecting lower flocculent solids, and washing with normal saline;
step 7) putting the flocculent solid collected in the step 6) into a refrigerator at the temperature of-24 ℃ for freezing for 2-4 hours, and carrying out freeze-drying and dewatering by a freeze-drying machine to obtain a solid massive acellular matrix;
step 8) mixing 0.5g of the acellular matrix prepared in the step 7), 0.45g of hyaluronic acid, 0.05g of sodium alginate and 0.02g of calcium chloride, and grinding for 30-60 minutes by using a vibration ball mill at a grinding speed of 2000-3000 r/min, wherein the specification of grinding balls is 20 mm, and the sample size is less than 10 microns;
step 9) placing the powder obtained by grinding in the step 8) under an ultraviolet lamp for irradiating for 2-4 hours, sterilizing, and placing in a refrigerator at-24 ℃;
step 10) mixing the sterilized powder obtained in the step 9) with normal saline according to the ratio of 1: 5-1: 50, stirring uniformly, and standing in a refrigerator at 4 ℃ for 24-36 hours to obtain the acellular matrix/hyaluronic acid composite gel.
3. The method for preparing a filling material for promoting blood vessel, collagen regeneration and adipose tissue repair according to claim 1, wherein: the adipose tissue in the step 1) is human adipose tissue or porcine adipose tissue.
4. A method for preparing a filling material for promoting blood vessel, collagen regeneration and adipose tissue repair according to claim 2, wherein: the hyaluronic acid in step 8) was 180 ppm molecular weight.
5. A filling material for promoting blood vessel, collagen regeneration and adipose tissue repair prepared by the method according to any one of claims 1 to 4.
6. Use of the filling material for promoting blood vessel, collagen regeneration and adipose tissue repair according to claim 7 in soft tissue filling and medical cosmetic filling.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210351631.2A CN114681674A (en) | 2022-04-02 | 2022-04-02 | Filling material for promoting blood vessel, collagen regeneration and adipose tissue repair, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210351631.2A CN114681674A (en) | 2022-04-02 | 2022-04-02 | Filling material for promoting blood vessel, collagen regeneration and adipose tissue repair, and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114681674A true CN114681674A (en) | 2022-07-01 |
Family
ID=82143910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210351631.2A Pending CN114681674A (en) | 2022-04-02 | 2022-04-02 | Filling material for promoting blood vessel, collagen regeneration and adipose tissue repair, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114681674A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150037436A1 (en) * | 2013-07-30 | 2015-02-05 | Musculoskeletal Transplant Foundation | Acellular soft tissue-derived matrices and methods for preparing same |
| US20170173217A1 (en) * | 2014-03-21 | 2017-06-22 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Methods for Preparation of a Terminally Sterilized Hydrogel Derived from Extracellular Matrix |
| WO2021125373A1 (en) * | 2019-12-17 | 2021-06-24 | 주식회사 엘앤씨바이오 | Medical composition comprising adipose tissue-derived extracellular matrix and method for preparing same |
| CN113633825A (en) * | 2021-06-28 | 2021-11-12 | 华中科技大学同济医学院附属协和医院 | Preparation method and application of bFGF-loaded heparinized acellular fat material |
| WO2022028244A1 (en) * | 2020-08-04 | 2022-02-10 | 宁波迪创医疗科技有限公司 | Tissue filling material, preparation method therefor, tissue engineering scaffold and use |
-
2022
- 2022-04-02 CN CN202210351631.2A patent/CN114681674A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150037436A1 (en) * | 2013-07-30 | 2015-02-05 | Musculoskeletal Transplant Foundation | Acellular soft tissue-derived matrices and methods for preparing same |
| US20170173217A1 (en) * | 2014-03-21 | 2017-06-22 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Methods for Preparation of a Terminally Sterilized Hydrogel Derived from Extracellular Matrix |
| WO2021125373A1 (en) * | 2019-12-17 | 2021-06-24 | 주식회사 엘앤씨바이오 | Medical composition comprising adipose tissue-derived extracellular matrix and method for preparing same |
| WO2022028244A1 (en) * | 2020-08-04 | 2022-02-10 | 宁波迪创医疗科技有限公司 | Tissue filling material, preparation method therefor, tissue engineering scaffold and use |
| CN113633825A (en) * | 2021-06-28 | 2021-11-12 | 华中科技大学同济医学院附属协和医院 | Preparation method and application of bFGF-loaded heparinized acellular fat material |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10500308B2 (en) | Decellularized adipose tissue | |
| CN108853569B (en) | Covalent cross-linked hyaluronic acid aerogel, hydrogel thereof and preparation method | |
| CN102198292A (en) | Scaffolds of umbilical cord decellularized Wharton jelly for tissue engineering and preparation method thereof | |
| Beck et al. | Chondroinductive hydrogel pastes composed of naturally derived devitalized cartilage | |
| CN106492284B (en) | A kind of preparation method of biodegradable filler and products thereof and application | |
| CN111603610B (en) | Preparation method of adipose tissue extracellular matrix | |
| CN112206356A (en) | Injectable bone repair hydrogel containing human umbilical cord mesenchymal stem cell exosomes and preparation method thereof | |
| CN106913907B (en) | Preparation method of cell growth scaffold with structural memory characteristic | |
| CN106421903A (en) | Blue shark fishskin collagen periodontium guided regeneration nanofiber membrane and preparing method thereof | |
| CN111407921A (en) | Medical hydrogel dressing, and preparation method and application thereof | |
| CN106421902B (en) | Rapid-gelation silk fibroin solution and preparation method thereof | |
| CN111840642A (en) | Preparation method and application of cartilage acellular matrix composite scaffold | |
| CN112316211A (en) | Cartilage extracellular matrix bionic injectable hydrogel and preparation method thereof | |
| CN113350567A (en) | Biocompatible polymer dressing based on collagen | |
| CN113929934B (en) | Degradation-resistant gelatin microsphere, artificial liver model, construction method and application thereof | |
| CN114681674A (en) | Filling material for promoting blood vessel, collagen regeneration and adipose tissue repair, and preparation method and application thereof | |
| CN114917410A (en) | Pomegranate type gel ball and preparation method thereof | |
| CN113648461A (en) | Preparation method and application of tissue engineering biological scaffold | |
| CN114206405B (en) | Medical composition comprising adipose tissue-derived extracellular matrix and method for producing same | |
| CN112691235A (en) | Preparation and application of fat-derived acellular matrix mainly prepared from human and pig by physical method | |
| CN108743618A (en) | A kind of preparation method and applications of syringeability stem cell aqueogel | |
| CN113440650B (en) | Method for preparing injectable hydrogel through gel crumbling recombination | |
| CN115746341A (en) | Polymer microsphere, preparation method thereof and application thereof in injection type tissue filler | |
| CN114306386A (en) | Application of antler stem cell conditioned medium | |
| CN114796614A (en) | Human adipose tissue acellular extracellular matrix and preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220701 |